среда, 7 сентября 2011 г.

AAP Encourages Parents To Immunize Their Children

The American Academy of
Pediatrics (AAP) highlights the importance and success of childhood
vaccines during National Infant Immunization Week, April 19-26. Vaccines
have eliminated or reduced many of the most devastating childhood illnesses
and are a critical component of the nation's public health efforts.


According to the U.S. Centers for Disease Control and Prevention,
before immunization:



-- Over 13,000 people in the U.S. contracted paralytic polio each year.
Thousands of children were left in crutches, braces, wheelchairs and iron
lungs.



-- 450 people died each year in the U.S. from measles, one of the most
infectious diseases in the world.



-- 600 American children died each year of Hib meningitis. Hundreds
more were left with deafness, seizures or mental retardation.



-- 9,000 people - mostly children - died of pertussis, or whooping
cough, in the U.S every year. Many infants who survived suffered permanent
brain damage.



-- 6,100 people in the U.S. died of invasive pneumococcal disease each
year. Many children developed long-term complications such as deafness or
seizures.



-- An estimated 20,000 infants born to infected mothers during a
rubella epidemic in 1964-65 contracted congenital rubella syndrome, an
illness whose symptoms include deafness, blindness and mental retardation.



-- 1,314 people contracted tetanus annually; one-fifth died of the
infection. Tetanus bacteria live in the soil and are resistant to
germ-killing cleaners.



Vaccines are the first and best line of defense to protect the infants
and children who are most vulnerable to these deadly viruses and bacteria.
While many young parents today have never witnessed a case of polio,
measles or rubella, these diseases still circulate in the world and would
return to the U.S. if immunization rates were to fall. Outbreaks of measles
and whooping cough in the U.S. in recent years show how quickly and easily
these diseases can spread among unvaccinated populations.



"Immunizing their child is the single best thing parents can do to
ensure their child's health," said Renee R. Jenkins, MD, FAAP, president of
the American Academy of Pediatrics. "The benefits of vaccines far outweigh
the risks. I firmly believe in the importance and safety of vaccines, as a
doctor, as a parent and as a new grandparent."



Experts in infectious diseases designed the vaccine schedule to protect
infants, children and adolescents when they are most susceptible to
infection with specific diseases. Parents who have questions about vaccines
should talk with their pediatrician. More information about vaccines is
available at aap or cdc.



The American Academy of Pediatrics is an organization of 60,000 primary
care pediatricians, pediatric medical subspecialists and pediatric
specialists dedicated to the health, safety and well-being of infants,
children, adolescents and young adults. Learn more at aap.



Buy Rocaltrol Without Prescription

вторник, 6 сентября 2011 г.

Blogs Comment On House Health Reform Bill, Obama Nominees, Other Topics

The following summarizes selected women's health-related blog entries.

"The Big Question: Could Abortion Be a Deal-Breaker on Health Care Reform?" Mary Ann Dreas/Tony Romm, The Hill's "Congress Blog": Dreas and Romm asked eight policymakers and advocates if abortion coverage could be a "deal-breaker" in attempts to enact health reform legislation. House Energy and Commerce Committee Chair Henry Waxman (D-Calif.) said that while abortion coverage is "an issue that divides people," he does not think it will be a deal-breaker because there are "a lot of pro-life members who ... feel we've done what's appropriate to ensure American people that we are using their taxpayer dollars well." Suzanne Poppema, board chair of the Physicians for Reproductive Choice and Health, also said the issue "shouldn't be a deal-breaker" because "women will always need abortion." She added that abortion services "should be treated like any other medical service -- not singled out for special attention." However, abortion-rights opponents Tom McClusky, senior vice president of FRC Action; John McManus, executive director of the John Birch Society; and Douglas Johnson, legislative director of the National Right to Life Committee, all said the issue should be a deal-breaker. Rep. Raul Grijalva (D-Ariz.) said that both abortion and immigration "are issues that are seen as potentially very decisive," while Rep. Brett Guthrie (R-Ky.) said he "would be seriously concerned if any bill passed the government that didn't protect the life of the unborn." Michael Wilson, executive director of Americans for Democratic Action, said abortion won't be a deal-breaker, adding that while he would like "a system that is as robust as possible with as much improvement as we can get, we know this is not the place to resolve the issue of choice" (Dreas/Romm, "Congress Blog," The Hill, 10/29).


"Does Focus on the Family Fund Abortions?" Amy Sullivan, TimeВ s В "Swampland": Antiabortion-rights groups have used a "fungibility" argument against abortion coverage under health reform, Sullivan writes. She adds that as these groups see it, if an insurer that covers abortion enters the health insurance exchange, then tax-payer supported premiums paid to the plan "help support that abortion coverage even if individual abortion procedures are paid for out of a separate pool of privately paid premium dollars." She asks, "But are those pro-life organizations holding themselves to the same strict standard?" Sullivan reports that Focus on the Family provides employees with health insurance from Principal, a company that covers abortion services. Even if the specific plan that Focus on the Family uses does not cover abortion services, its employees "still pay premiums to a company that funds abortions," Sullivan writes. She says, "If health reform proposals have a fungibility problem, then Focus does as well" (Sullivan, "Swampland," Time, 10/28).


"10 Reasons Abortion Must Be Covered," Lynn Harris, SalonВ 's "Broadsheet": "[F]or right reasons or wrong, there is a question" of why abortion services should be covered under health care reform legislation, Harris writes. Harris offers 10 reasons to include abortion coverage in health reform, including that it is "legal medical care" and that is "one of the most common surgical procedures in America." Abortion services are "already broadly covered" under private insurance plans, she continues. The abortion rate will not increase by covering the procedure, and covering abortion services "makes abortion safer" and is "what the people want," Harris writes. In addition, "[e]xcluding abortion from coverage sends us down a slippery 'moral' slope," she writes, adding that Frances Kissling recently said that federal policies based on the idea that people "should not be forced to see their premiums used to cover things they consider immoral" would bring the U.S. back to the time when individual plans for unmarried women did not include contraception or maternity coverage. In addition, while some opponents argue that abortion is an "elective" procedure, they ignore the many other procedures that are covered without the need for any moral debate or proof of medical necessity. Harris continues that "[w]ithout coverage there is no 'choice,'" adding, "Even with the best prevention measures, there will be unintended pregnancies." She concludes with a quote from Megan Carpentier, news and politics editor for Air America Radio, who said that abortion should be covered because "sometimes abortion is medically necessary, and the government shouldn't be writing regulations from Washington that tell a woman in Kansas when that is." Carpentier added that "eliminating coverage that currently exists through federal law is just another back-door way for the antiabortion movement to make it more difficult and expensive for women to get a legal medical procedure, since they can't convince women not to have abortions on the 'merits' of their arguments" (Harris, "Broadsheet," Salon, 10/28).


"Stupak Still Unhappy With Health Care Reform, Abortion Provision," Tony Romm, The HillВ s В "Blog Briefing Room": Rep. Bart Stupak (D-Mich.), who is threatening to block the House health reform bill (HR 3962) unless Democrats allow a vote on an amendment that would add language further restricting abortion coverage, is not satisfied with progress on the issue, Romm writes. In a statement released Thursday, Stupak said the bill "still does not do enough to prevent federal funding from going to abortion services." He also said he is "disappointed" that the Capps amendment language is included in the bill. Romm writes, "All eyes have been on Stupak since he announced he had the support of 39 other lawmakers and would scuttle attempts to bring health care reform to the House floor unless the Democratic leadership addressed his concerns." Romm adds, "Both sides have tried to negotiate that dilemma for some time now, but they have not been able to strike a deal. It is still unclear whether a vote on Stupak's amendment will even take place" (Romm, "Blog Briefing Room," The Hill, 10/29).


"Senate Leader Blasts Holdup o[f] Obama's Nominees," Kate Phillips, New York TimesВ ' "The Caucus": On Thursday, Senate Majority Leader Harry Reid (D-Nev.) "slammed Republicans for slowing down, and in some cases, blocking the confirmation of nominees for various posts in the Obama administration," Phillips states. Reid noted that several top health care posts at the federal level had yet to be filled. According to the Phillips, nine HHS nominees have been confirmed and eight are awaiting confirmation. Phillips reports that the confirmations of several other "high-profile nominees ... have been stalled or waylaid," including Department of Justice nominee Dawn Johnsen, whose "nomination by our count seems to be one of the longest delayed." Johnsen is nominated for deputy attorney general for the Office of Legal Counsel, "which offers critical advice to the president on everything, ranging from executive authority to interrogation methods," Phillips says. However, "Republicans have long objected to the fact that she served as legal counsel for an abortion-rights organization years ago, among other duties, and have taken issue with views they find controversial," she writes (Phillips, "The Caucus," New York Times, 10/29).


"What Catholics Want in Health Care Reform: Should We Cover Some People, Some Parts of People, or All Parts of Everybody?" Jon O'Brien/Sara Morello, Washington PostВ 's "On Faith": There is a "curious divide" in the health reform debate "about what exactly health care is or what it should be" and "who and what should be left out of the final plan," according to O'Brien and Morello, Catholics for Choice's president and vice president, respectively. While these are "not unreasonable questions," the "answers that some people, who claim to speak for American Catholics, provide are not reflective of what Catholics in the United States believe," they write, noting that a poll of nearly 1,000 U.S. Catholics found that most "think providing health care to all people who need it is a matter of social justice." The poll respondents said that "their understanding of social justice includes extending health care to the whole person, not just some parts of people," including covering reproductive health services and abortion. Catholics for Choice "believe[s] that all people should have access to the health care they need," and 73% of the poll's respondents agreed and more than 60% believe contraception should be covered by insurance, O'Brien and Morello write. "We believe that abortion should be covered by insurance -- whether private or government subsidized," they continue. "Depending on the circumstances, as many as 84% agree with us, and when the question really comes down to respecting a woman's conscience in regard to her own health, a full half of Catholics polled agree that abortion should be covered whenever a woman and her doctor decide she needs it," according to O'Brien and Morello. They write that their "instinct" tells them that "Catholics are far more progressive than their bishops, ... and our poll results prove it" (O'Brien/Morello, "On Faith," Washington Post, 10/29).


"Rehearsal for an Anti-Choice Protest: 'Okay, You Stand Here and She's Gonna Whip You With This Whip,'" Amanda Terkel, ThinkProgress: Randall Terry, founder of the antiabortion-rights group Operation Rescue, recently encouraged supporters to film videos of themselves burning effigies of House Speaker Nancy Pelosi (D-Calif.) and Senate Majority Leader Harry Reid (D-Nev.), Terkel says. She writes that ThinkProgress spotted Terry on Capitol Hill this week with signs and costumes, conversing with congressional staffers as they entered their offices. Terry, as he was "preparing for his charade this morning," told followers, "'Okay, you stand here and she's gonna whip you with this whip,'" according to Terkel. Organizers say the protest is the first of a series that will continue until Nov. 12 (Terkel, ThinkProgress, 10/29).


"Peru's Highest Court Rules Against EC," Elizabeth Westley, Below the Waist: Peru's Constitutional Court ruled last week to block the Ministry of Health from distributing no-cost emergency contraception, Westley, coordinator of the International Consortium for Emergency Contraception, writes. The court said that the Ministry of Health failed to prove "the inexistence of the abortifacient effect, the inhibition of the implantation of the fertilized ovum in the endometrium," thus concluding that EC could cause abortion and violate Peru's Constitution. Westley writes that the ruling contradicts a growing body of literature -- including from ICEC and the World Health Organization -- "that shows delaying or preventing ovulation is the most likely and perhaps only mechanism by which EC effectively prevents pregnancy." EC can continue to be sold in Peru but only with a package insert warning that it might cause an abortion. "This Peru case is very similar to ones in Ecuador and Chile, and may represent a trend toward protecting the rights of the 'conceived' using weak science as a strategy to limit access to EC," Westley writes. "Clearly, some Latin American courts are now considering that life begins at conception and not at implantation," she adds (Westley, Below the Waist, 10/27).


"The Gender Gap, Around the World," Catherine Rampell, New York TimesВ ' "Economix": The World Economic Forum on Tuesday released its annual Global Gender Gap Report, and the U.S. "was ranked No. 31, three spots lower than it was last year," Rampell writes. The report "tries to assess how well countries 'are dividing their resources and opportunities among their male and female populations, regardless of the overall levels of these resources and opportunities.'" Four Nordic countries -- Iceland, Norway, Finland and Sweden -- topped the list. The assessments are based on four components: economic participation and opportunity, educational attainment, political empowerment, and health and survival. The organization says the report is intended to show the percentage of a nation's gender gap that has closed, meaning that a high score represents a society with greater gender parity (Rampell, "Economix," New York Times, 10/28).

Reprinted with kind permission from nationalpartnership. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.


© 2009 The Advisory Board Company. All rights reserved.


Buy Azathioprine Without Prescription

Tattooing Improves Response To DNA Vaccine

A tattoo can be more than just a fashion statement it has potential medical value, according to an article published in the online open access journal, Genetic Vaccines and Therapy.


Martin MГјller and his team at the Deutsches Krebsforschungszentrum (German Cancer Research Center), Heidelberg, Germany, have shown that tattooing is a more effective way of delivering DNA vaccines than intramuscular injection. Using a coat protein from the human papillomavirus (HPV, the cause of cervical cancer) as a model DNA vaccine antigen, they compared delivery by tattooing the skin of mice with standard intramuscular injection with, and without, the molecular adjuvants that are often given to boost immune response.


The tattoo method gave a stronger humoral (antibody) response and cellular response than intramuscular injection, even when adjuvants were included in the latter. Three doses of DNA vaccine given by tattooing produced at least 16 times higher antibody levels than three intramuscular injections with adjuvant. The adjuvants enhanced the effect of intramuscular injection, but not of tattooing.


Tattooing is an invasive procedure done with a solid vibrating needle, causing a wound and sufficient inflammation to 'prime' the immune system. It also covers a bigger area of the skin than an injection, so the DNA vaccine can enter more cells. These effects may account for the stronger immune response arising from introducing a DNA vaccine into the body by tattooing. Of course, the tattooing approach may not be to everyone's taste as it is likely to hurt but the researchers believe that it could have a role in, for instance, routine vaccination of cattle or in delivering therapeutic (rather than prophylactic) vaccines to humans.


'Vaccination with naked DNA has been hampered by its low efficiency' says MГјller. 'Delivery of DNA via tattooing could be a way for a more widespread commercial application of DNA vaccines'


BIOMED CENTRAL LIMITED

Middlesex House

34-42 Cleveland Street

London

W1T 4LB

biomedcentral

Buy Motilium Without Prescription

BSD Medical Launches Award-Winning Website As Part Of Direct To Consumer Communications Strategy

BSD Medical Corp.
(Amex: BSM) today announced that its newly launched website
flowersforhope has already been chosen as a "People's Choice
Winner" as well as being nominated for a "Flash Forward Award," which is
one of the highest website awards possible. The new website, "The Hope
Garden," provides an innovative virtual flower garden experience intended
to offer hope and encouragement for those struggling with cancer. In
addition to this service, this new website is meant to direct large numbers
of people to the BSD patient website treatwithheat where they can learn more about BSD's cutting-edge therapy for cancer, making The Hope
Garden a very tangible contribution to hope for those with cancer.


"We believe that the Hope Garden has the potential to bring large
numbers of people to our patient website, and at the same time provide a
valuable service to those faced with cancer," said Hyrum A. Mead, President
of BSD Medical. "We are already seeing the number of visits grow as this
website has begun to gain exposure over the last few days, with the number
of visits to the Hope Garden website growing from 150 visits to over 5,000
per day. This in turn has increased visits to our treatwithheat website
threefold, providing valuable information about our cancer therapy that can
offer new hope for cancer patients. Viral communication, or word of mouth
communication as it is referred to offline, is a proven internet strategy
that encourages individuals to pass on a message to others, creating the
potential for exponential growth in the message's exposure and influence.
This strategy takes advantage of rapid multiplication to expose the message
to thousands and on to millions of people."


The website was created by Salt Lake City-based Richter7, a
full-service advertising and marketing firm with expertise in the
development of medical and other websites. Richter7 has developed and
implemented successful interactive websites for Medtronic, Biolase, Mrs.
Fields Cookies and others.


Visitors to the site can navigate through the garden, clicking on
flowers they would like to view. To plant a flower of their own, visitors
click "Plant Flower," then select the type and color of flower they would
like to plant. Visitors then fill in their name, the name of the person
they are planting the flower for, an e-mail address for the recipient and
their message of hope. They then click "Preview" to review their message,
and then click on the "Plant" button. Visitors can also search for a
specific person's flower by typing in the name or e-mail address of the
person who planted it in the box at the bottom of the screen.


BSD Medical Corp. is a leading developer of systems that deliver
precision-focused microwave/RF energy to heat diseased sites in the body,
raising them to therapeutic temperatures as required for a variety of
medical treatments, including cancer. For further information about BSD
Medical and its technologies visit the BSD corporate website at
BSDMedical.


Statements contained in this press release that are not historical
facts are forward-looking statements, as that item is defined in the
Private Securities Litigation Reform Act of 1995. All forward-looking
statements and projections or expectations of future events, including the
prospects for future sales of the Company's cancer therapy systems based on
increasing patient exposure to the Company's cancer therapy are subject to
risks and uncertainties detailed in the Company's filings with the
Securities and Exchange Commission.


BSD Medical Corp.

BSDMedical

Buy Arava Without Prescription

Individuals With Partial Hearing Loss May Benefit From Hybrid Cochlear Implant

Hearing loss can affect anyone, at any time. But it can be especially frightening for someone who suddenly starts to lose his hearing during adulthood. Tom Groves, 77, first noticed his diminishing hearing when he was in his early 40s. He was unable to hold conversations with large groups of people; found it nearly impossible to socialize in high-background noise environments like restaurants; and couldn't enjoy radio, TV and movies unless they were captioned. Now, Groves is hearing much better than he has in 30 years, thanks to an experimental hybrid cochlear implant.


Northwestern Memorial Hospital is one of nine centers in the U.S., and the only in Illinois, that is participating in a study investigating the effectiveness of a new cochlear implant device that aims to restore hearing for individuals with high-frequency hearing loss and functional low-frequency hearing.


This group of patients doesn't meet the criteria for conventional cochlear implants because they have near perfect residual hearing in low pitches that allows them to perform well on tests used to determine candidacy for traditional implants. However, their hearing in high pitches is so poor that a hearing aid is not helpful, making them ideally suited for the hybrid implant which addresses both issues.


"We are hopeful that the hybrid cochlear implant will provide a subset of people who were previously not candidates for an implantable device the opportunity to test the device to determine if they can experience sound again," said Northwestern Medicine neurotologist Andrew Fishman, MD, principal investigator of the study, staff in the departments of otolaryngology and neurosurgery at Northwestern University's Feinberg School of Medicine, and Mr. Groves' cochlear implant surgeon. "The potential for patients with a significant amount of residual hearing, but a large amount of high-frequency hearing loss, to have an alternative to hearing aids would be a great improvement to what is currently available."


Cochlear implants were FDA approved in 1984 as a treatment option for restoring hearing in people with severe and profound hearing loss. The surgical implant system is designed to stimulate the auditory nerve by bypassing damaged parts of the ear. A small battery-operated mini "computer" and microphone are worn on the outside of the ear and convert sounds into electric signals. The signals are then transmitted to implant electrodes in the cochlea, which stimulate the nerve endings so sound can be perceived by the brain.


The hybrid cochlear implant works in the same way as traditional cochlear implants, stimulating nerve endings in the cochlear so that high-pitched sounds can be heard. In addition, it also involves amplification for low-pitched sounds, similar to a hearing aid. Like traditional cochlear implants, the hybrid version is worn outside the ear and converts sounds into acoustic and electric signals.


"The surgical implantation of cochlear devices is typically done on an outpatient basis, and usually with non-serious complications, aside from mild discomfort following surgery," said Northwestern Medicine otolaryngologist Alan Micco, MD, co-investigator of the study and chief of otology/neurotology at the Feinberg School of Medicine. "A few weeks following surgery, the activation process and fine-tuning take place to determine what audio thresholds work best for the individual, and sounds can usually be perceived shortly thereafter."


Post-activation evaluations take place at three, six and 12 months following the initial activation process to assess progress of the cochlear implant. An audiologist will also test the implant to determine if participants are able to understand words, sentences in noisy and quiet environments, as well as music recognition.


A few months post-surgery, Groves is happy to have some of his hearing restored. "I'm very excited and encouraged by my experience with the implant. I know I'm hearing better than I have for many, many years and for that I'm very grateful."


Source: Northwestern Memorial Hospital

Buy Pyrantel Pamoate Without Prescription

New Statistical Method For Genetic Studies Could Cut Computation Time From Years To Hours

In the ongoing quest to identify the genetic factors involved in disease, scientists have increasingly turned to genome-wide association studies, or GWAS, which enable the scanning of up to a million genetic markers in thousands of individuals.



These studies generally compare the frequency of genetic variants between two groups - those with a particular disease and healthy individuals. Differences in the frequency of a given variant suggest the variant may be involved in the disease.



Over the last few years, such studies have successfully implicated hundreds of genes in human disease, and the research has been used to identify risk and protective factors for asthma, cancer, diabetes, heart disease, mental illness and other conditions.



But genome-wide association studies aren't perfect. In fact, the genealogy of study participants can sometimes prove a stumbling block to accurate findings.



"Unfortunately, differences in frequencies can arise for reasons unrelated to the disease if the individuals collected have ancestry from different regions of the world," said Eleazar Eskin, associate professor of computer science at the UCLA Henry Samueli School of Engineering and Applied Science, who holds a joint appointment in the department of human genetics at the David Geffen School of Medicine at UCLA.



"This problem, called 'population structure,' has led to many apparent discoveries of genes involved in disease which later turned out to be artifacts," he said.



In a new study to be published in the April edition of the journal Nature Genetics (currently available online), Eskin and his research group unveil a new computational strategy for GWAS that corrects for population structure and is both faster and easier to use.



One of the basic assumptions in typical GWAS is that participating individuals are "unrelated," and investigators typically perform screening procedures to ensure that pairs of individuals are not close relatives. However, due to the complex history of the human population, none of the individual pairs are perfectly unrelated, and each individual pair is somewhat distantly related to various degrees. This is referred to as "pairwise relatedness."



"Such a variety in degrees of relatedness - which we call 'sample structure' - can be manifested into two different forms: population structure and hidden relatedness. While typical statistical methods for GWAS handle only either of the two forms, our method can handle both aspects of sample structure simultaneously in a computationally efficient manner," said Hyun Min Kang, an assistant research professor in biostatistics at the University of Michigan and an author of the study.



"Moreover, if the samples come from a very homogeneous population, it is possible that some of the subjects are, in fact, distantly related," said Chiara Sabatti, professor of human genetics and statistics at UCLA and a corresponding author of the study. "In the analysis of GWAS, it is necessary to correct for such sample structure, which can lead to spurious association signals. The methods presented in our paper allow researchers to do this in a manner that is both fast and effective."



Eskin's team worked with a data set of 5,000 people from Finland who were born in the same year, tracked over an extensive amount of time, and had a large amount of population relatedness.



The 5,000 people produced a data set of 300,000 variants. From these 300,000 points of variation, the group examined pairwise relatedness between individuals, which means they compared the number of mutations each shared. From the mutations, Eskin's group could estimate how related individuals were to each other.



"It was very interesting to see how much these pairwise relations explained of the trait," Eskin said. "So what we did in this paper is we proposed a statistical method that also allowed us to correct for a wide range of sample structure by explicitly accounting for pairwise relatedness between individuals using high-density markers in modeling the distribution of observable traits."



This variance component in the new strategy, called EMMAX (Efficient Mixed Model Association Expedited), would capture the complex mixture of both population structure and hidden relatedness, direct byproducts of genealogy, and correct for these relationships when performing genetic mapping.



"Capitalizing on the characteristics of complex traits in humans, we made a few simplifying assumptions that allowed us to dramatically increase the speed of computations, making our approach readily applicable to genome-wide association studies with tens of thousands of samples," Eskin said.



"Our variance component model is actually a widely known classical model for genetic mapping," Kang said. "However it was too computationally costly to be applied to the current scale of GWAS involving thousands of individuals with hundreds of thousands of genetic variants because even the fastest method - which we previously developed - took years of computational time to analyze the data once. We further expedited the method by capitalizing the characteristics of most human association studies, reducing the computational time from years to hours."



According to Eskin, their method will also have a large impact on admixed populations, which are basically samples of individuals who have ancestry from multiple regions around the world. Studies on Los Angeles, for example, would benefit from this method greatly, as people in the city are very ethnically diverse and it's difficult to obtain very accurate estimates of people's ancestry.



The study was supported in part by the National Toxicology Program/National Institute of Environmental Health Sciences.



Source:

Wileen Wong Kromhout

University of California - Los Angeles

Buy Macrobid Without Prescription

First Patients Undergo Surgery In Northwest Biotherapeutics' Phase II Brain Cancer Trial

Northwest
Biotherapeutics, Inc. (OTC Bulletin Board: NWBT.OB), a biotechnology
company focused on cancer immunotherapy, today announced that the first two
patients in its pivotal Phase II clinical trial have undergone surgery for
newly diagnosed Glioblastoma multiforme (GBM), which is the first step in
the preparation of the Company's DCVax(R)-Brain treatment. The surgeries
took place at Henry Ford Hospital in Detroit, MI.


"We are very pleased to begin the patient accrual process for this
Phase II trial, and anticipate completing enrollment in Q4 of this year. We
are also working with nine other clinical sites to accelerate patient
accrual during the next few months," stated Alton Boynton, President of
Northwest Biotherapeutics. Dr. Boynton further stated, "I consider this a
major milestone for NWBT and look forward to rapid patient accrual in this
important clinical trial."



The DCVax(R)-Brain treatment consists of three initial immunizations at
2 week intervals, followed by four booster injections at 2- and 4-month
intervals for the remainder of year one, and thereafter semi-annual
maintenance injections for an additional two years. DCVax(R)-Brain showed
no toxicity in previous studies in over 100 patients.



The DCVax(R)-Brain Phase II clinical trial is based on two Phase I
studies carried out at UCLA under the direction of Linda Liau, M.D., Ph.D.,
Director of the Malignant Brain Tumor Program at the UCLA School of
Medicine. Each of the trials included both newly diagnosed (early stage)
GBM, and recurrent (late stage) GBM. DCVax(R)-Brain has doubled the time to
progression and the overall survival time in both the early and the late
stage patients. The data for those trials continue to mature.



In the newly diagnosed GBM patients, DCVax(R)-Brain has increased the
time to recurrence or progression of disease as described in Kaplan Meier
plots from 8.1 months with standard of care treatments to 18.1 months with
DCVax(R)- Brain (p< 0.00001). Kaplan Meier plots also showed that
DCVax(R)-Brain increased median overall survival from 17 months with
standard of care treatments to 33.8 months (p=0.0044) for DCVax(R)-Brain
treated patients. Ten of the 19 patients remain alive for periods ranging
to date from 10 to 80 months. Similarly, in recurrent (late stage)
patients, DCVax(R)-Brain has increased median survival from 6.4 months for
historical controls receiving standard of care to 13.2 months for patients
receiving DCVax(R)-Brain.



DCVax(R)-Brain uses a patient's own tumor, surgically removed as part
of the standard of care, to prepare a mix of their personal cancer
biomarkers. These personal cancer biomarkers are then loaded into the
patient's own dendritic cells (the master cells responsible for starting
and managing the body's overall immune response), and injected back into
the patient through a simple intra-dermal injection, similar to an insulin
shot, at various intervals over a three year period. The DCVax(R)-Brain
Phase II trial is designed and powered as a pivotal trial, and will involve
141 patients. All patients will receive full standard of care treatment,
which includes surgery, radiation and chemotherapy, and approximately 94 of
these patients will also receive DCVax(R)-Brain. A sufficient quantity of
each patient's personal therapeutic cancer vaccine is prepared in a single
manufacturing procedure to provide for 3 years of treatment.



About Northwest Biotherapeutics



Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products that treat cancers more effectively than
current treatments, without toxicity, on a cost-effective basis. The
Company has two broad platform technologies: dendritic cell-based vaccines,
and therapeutic antibodies. The Company's three lead product candidates
are:



DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of
Glioblastoma multiforme, which has entered into a large Phase II pivotal
clinical trial cleared by the FDA;


DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment
of hormone independent non-metastatic prostate cancer, which is ready to
enter a Phase III clinical trial cleared by the FDA; and


Monoclonal antibodies to CXCR4, which are in late pre-clinical
development for the treatment of multiple cancers. For further
information, please visit the company web site at nwbio/.



The Company also has a robust pipeline of additional products cleared
by FDA for early stage clinical trials in multiple other cancers.



Statements made in this news release that are not historical facts are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as "expects," "believes,"
"intends," and similar expressions are intended to identify forward-looking
statements. Actual results may differ materially from those projected in
any forward-looking statement. Specifically, there are a number of
important factors that could cause actual results to differ materially from
those anticipated, such as the company's ability to raise additional
capital, risks related to the company's ability to enroll patients in its
Phase II clinical trial of DCVax(R)-Brain and complete the trial on a
timely basis, the uncertainty of the clinical trials process, the timely
performance of third parties, and whether DCVax(R)-Brain will demonstrate
safety and efficacy and the timely performance of third parties. Additional
information on these and other factors, which could affect the company's
results, is included in its Securities and Exchange Commission ("SEC")
filings. Finally, there may be other factors not mentioned above or
included in the company's SEC filings that may cause actual results to
differ materially those projected in any forward-looking statement. You
should not place undue reliance on any forward-looking statements. The
company assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as
required by securities laws.


Northwest Biotherapeutics, Inc.

nwbio/

Buy Diflucan Without Prescription